Gram-positive resistance: Challenge for the development of new antibiotics

Journal of Antimicrobial Chemotherapy

Volumn 39, Issue SUPPL. A, 1997, Pages 1-6

  Baquero, Fernando ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; DALFOPRISTIN; LINCOSAMIDE; MACROLIDE; METICILLIN; PENICILLIN DERIVATIVE; STREPTOGRAMIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CLOSTRIDIUM; COAGULASE NEGATIVE STAPHYLOCOCCUS; CORYNEBACTERIUM; ENTEROCOCCUS; LISTERIA; MULTIDRUG RESISTANCE; PEPTOSTREPTOCOCCUS; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

EID: 0031002376     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/39.suppl_1.1     Document Type: Review

References (33)

1. Schalberg, D. R. (1994). Resistant Gram-positive organisms. Annals of Emergency Medicine 3, 462-4.
2. Hofmann, J., Cetron, M. S., Farley, M. M., Baughman, W. S., Facklam, R. R., Elliott, J. A. et al. (1995). The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. New England Journal of Medicine 333, 481-6.
3. Appelbaum, P. C. (1996). Emerging resistance to antimicrobial agents in Gram-positive bacteria: pneumococci. Drugs 51, Suppl., 1-5.
4. Friedland, I. R. & McCracken, G. H. (1994). Management of infections caused by antibiotic-resistant Streptococcus pneumoniae. Drug Therapy 331, 377-82.
5. Spangler, S. K., Jacobs, M. R. & Appelbaum, P. C. (1994). In-vitro susceptibilities of 185 penicillin-susceptible and -resistant pneumococci to WY-49605 (SUN/SY 5335), a new oral penem, compared with those to penicillin G, amoxycillin-clavulanate, cefixime, cefaclor, cefpodoxime, cefuroxime, and cefdinir. Antimicrobial Agents and Chemotherapy 38, 2902-40.
6. Spika, J. S., Facklam, R. R., Plikaytis, B. D., Oxtoby, M. J. & The Pneumococcal Surveillance Working Group. (1991). Antimicrobial resistance of Streptococcus pneumoniae in the United States. Journal of Infectious Diseases 163, 1273-8.
7. Thornsberry, C. (1995). Trends in antimicrobial resistance among today's bacterial pathogens. Pharmacotherapy 15, 3-5S.
8. Appelbaum, P. C. (1992). Antimicrobial resistance in Streptococcus pneumoniae: an overview. Clinical Infectious Diseases 15, 77-83.
9. Baquero, F. (1995). Pneumococcal resistance to beta-lactam antibacterials: a global geographic overview. Microbial Drug Resistance 2, 115-20.
10. Breiman, R. F., Butler, J. C., Tenover, F. C., Elliot, J. A. & Facklam, R. R. (1994). Emergence of drug resistant pneumococcal infection in the United States. Journal of the American Medical Association 271, 1831-5.
11. Geslin, P., Fremaux, A., Sissia, G., Spicq, C. & Aberrance, S. (1994). Epidémiologie de la résistance aux antibiotiques de Streptococcus pneumoniae en France. Réseau national de surveillance (1984-1993). Medecine et Maladies Infectieuses 24, 948-61.
12. Tomasz, A. (1995). The pneumococcus at the gates. New England Journal of Medicine 333, 514-5.
13. Pallares, R., Linares, J., Vadillo, M., Cabellos, C., Manresa, F. & Viladrich, P. F. (1995). Resistance to penicillin and cephalosporin and mortality from severe pneumococcal pneumonia in Barcelona, Spain. New England Journal of Medicine 333, 474-80.
14. Cormican, M. G. & Jones, R. N. (1996). Emerging resistance to antimicrobial agents in gram-positive bacteria: enterococci, staphylococcus and nonpneumococcal streptococci. Drugs 51, Suppl., 6-12.
15. Bochud, P. Y., Eggiman, P., Calandra, T., Van Meile, G., Saghafit, L. & Francioli, P. (1994). Bacteraemia due to viridans streptococci in neutropenic patients with cancer: clinical spectrum and risk factors. Clinical Infectious Diseases 18, 25-31.
16. Portgierter, E., Carmichael, M., Koornhoff, H. J. & Chalkley, L. J. (1992). In vitro and microbial susceptibility of viridans streptococci isolated from blood cultures. European Journal of Clinical Microbiology and Infectious Diseases 11, 543-6.
17. Jones, R. N., Barry, A. L. & Gardiner, R. V. (1989). The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective trial of isolates from 40 medical centers. Diagnostic Microbiology and Infectious Diseases 12, 383-94.
18. Gomez-Garces, J. L., Alos, J. I. & Cogollos, R. (1994). Bacteriologic characteristics and antimicrobial susceptibility of 70 clinically significant isolates of Streptococcus milleri group. Diagnostic Microbiology and Infectious Diseases 19, 68-73.
19. Neu, H. C. (1992). The crisis in antibiotic resistance. Science 257, 1064-72.
20. Morris, J. G., Shay, D. K., Hebden, J. N., McCarter, R. J., Perdue, B. E., Jarvis, W. et al. (1995). Enterococci resistant to multiple antimicrobial agents including vancomycin. Annals of Internal Medicine 123, 250-9.
21. Schalberg, D. R., Culver, D. H. & Gaynes, R. P. (1991). Major trends in the microbial etiology of nosocomial infections. American Journal of Medicine 91, Suppl., 72-5S.
22. Anon. (1993). Nosocomial enterococci resistant to vancomycin - United States 1989-1993. MMWR Morbidity and Mortality Weekly Report 42, 597-9.
23. Rubinstein, E. & Keller, N. (1996). Future prospects and therapeutic potential of streptogramins. Drugs 51, Suppl., 27-31.
24. Voss, A. & Doebbeling, B. N. (1995). The worldwide prevalence of methicillin-resistant Staphylococcus aureus. International Journal of Antimicrobial Agents 5, 101-6.
25. Bauernfeind, A., Thornsberry, C. & Grassi, G. G. (1994). Panel discussion: quinolone resistance in Gram-positive bacteria. Infectious Diseases in Clinical Practice 3, S133-5.
26. Archer, G. L. & Climo, M. W. (1994). Antimicrobial susceptibility of coagulase-negative staphylococci. Antimicrobial Agents and Chemotherapy 38, 2231-7.
27. Swartz, M. N. (1994). Hospital acquired infections: diseases with increasingly limited therapies. Proceedings of the National Academy of Sciences of the United States of America 91, 2420-7.
28. Jones, R. N., Kehberg, E. N., Erwin, M. E., Anderson, S. C. & The Fluoroquinolone Resistance Surveillance Group. (1994). Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States. I. Study on the threat of emerging resistances: real or perceived? Diagnostic Microbiology and Infectious Diseases 19, 203-15.
29. Schwalbe, R. S., Stapleton, J. T. & Gilligan, P. H. (1987). Emergence of vancomycin-resistance in coagulase-negative staphylococci. New England Journal of Medicine 316, 927-31.
30. Pechère, J.-C. (1996). Streptogramins: a unique class of antibiotics. Drugs 51, Suppl., 13-9.
31. Finch, R. G. (1996). Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use. Drugs 51, Suppl., 31-37.
32. Pepper, K. & Bouanchaud, D. (1996). In vitro activity of quinupristin/dalfopristin (RP 59500) against Gram-positive pathogens: an update. Expert Opinion on Investigational Drugs 5, 357-63.
33. Johnson, C. J., Slavoski, L., Schawartz, M., May, P., Pitsakis, P. G., Shur, A. L. et al. (1995). In vitro activity of RP 59500 (quinupristin/dalfopristin) against antibiotic-resistant strains of Streptococcus pneumoniae and enterococci. Diagnostic Microbiology and Infectious Diseases 21, 169-73.